Related references
Note: Only part of the references are listed.Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer
Henrik Green et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
Global variation in CYP2C8-CYP2C9 functional haplotypes
William C. Speed et al.
PHARMACOGENOMICS JOURNAL (2009)
Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards
A. M. Peiro et al.
PHARMACOLOGICAL RESEARCH (2009)
Effect of Concomitant Artesunate Administration and Cytochrome P4502C8 Polymorphisms on the Pharmacokinetics of Amodiaquine in Ghanaian Children with Uncomplicated Malaria
George O. Adjei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: Evidence for mechanism-based inhibition of CYP2C8 in vivo
A. Tornio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(+)-Ibuprofen Hydroxylation in Vitro
Shu-Ying Chang et al.
DRUG METABOLISM AND DISPOSITION (2008)
Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers
P. Dorado et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Determinants of cytochrome P4502C8 substrate binding -: Structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid
Guillaume A. Schoch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding
Gerardo Blanco et al.
PHARMACOGENETICS AND GENOMICS (2008)
Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers
Rosario Lopez-Rodriguez et al.
PHARMACOLOGICAL RESEARCH (2008)
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism
C. Rodriguez-Antona et al.
PHARMACOGENOMICS JOURNAL (2008)
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone
Aleksi Tornio et al.
DRUG METABOLISM AND DISPOSITION (2008)
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer
Sharon Marsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk
Katherine N. Theken et al.
PHARMACOGENOMICS (2007)
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
S. Marsh et al.
PHARMACOGENOMICS JOURNAL (2007)
Amodiaquine metabolism is impaired by common polymorphisms inCYP2C8: Implications for malaria treatment in Africa
S. Parikh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers
Mari Jiko et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetics of thiazolidinedione therapy
Christina L. Aquilante
PHARMACOGENOMICS (2007)
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population
Yoshiro Saito et al.
PHARMACOGENETICS AND GENOMICS (2007)
Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen
Aleksi Tornio et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues
Tracy C. DeLozier et al.
DRUG METABOLISM AND DISPOSITION (2007)
CYP2C8 and antimalaria drug efficacy
J. P. Gill et al.
PHARMACOGENOMICS (2007)
Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 genotypes
Ann K. Daly et al.
GASTROENTEROLOGY (2007)
Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human Hepatocytes
Koki Kojima et al.
DRUG METABOLISM AND PHARMACOKINETICS (2007)
The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects
Rasmus S. Pedersen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Pharmacokinetics and pharmacodynamics of rosiglitazone in elation to CYP2C8 genotype
Julia Kirchheiner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
Yoshihisa Shitara et al.
PHARMACOLOGY & THERAPEUTICS (2006)
The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone
Aleksi Tornio et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro:: Potential for interactions with CYP2C8 inhibitors
Tiina Jaakkola et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide
M Niemi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer
H. Yamaguchi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Statin safety: A systematic review
M Law et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases
EF Johnson et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
A Henningsson et al.
CLINICAL CANCER RESEARCH (2005)
No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARδ and PPARγ act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma
LE McGreavey et al.
PHARMACOGENETICS AND GENOMICS (2005)
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro:: Effect of fibrates and rifampicin
LI Kajosaari et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Cyclosporine markedly raises the plasma concentrations of repaglinide
LI Kajosaari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage
RA Wilke et al.
PHARMACOGENETICS AND GENOMICS (2005)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1
M Nakajima et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Cytochrome P4502C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance
RA Totah et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population
H Hichiya et al.
DRUG METABOLISM AND DISPOSITION (2005)
Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis
H Ozaki et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2005)
An association study of 43 SNPs in 16 candidate genes with atorvastatin response
JF Thompson et al.
PHARMACOGENOMICS JOURNAL (2005)
The effect of the cytochrome P450CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects
C Martinez et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects
MW Hruska et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Structure of human microsomal cytochrome P4502C8 - Evidence for a peripheral fatty acid binding site
GA Schoch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin
C Ishikawa et al.
JOURNAL OF HUMAN GENETICS (2004)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P4502C8 and 2C9 amino acid polymorphisms
E García-Martín et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Acute and clinically relevant drug-induced liver injury:: a population based case-control study
FJ de Abajo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use
C Martinez et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Pharmacogenetic study of statin therapy and cholesterol reduction
DI Chasman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Moving towards individualized medicine with pharmacogenomics
WE Evans et al.
NATURE (2004)
Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes
KA Kim et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Polymorphism in CΥP2C8 is associated with reduced plasma concentrations of repaglinide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
M Niemi et al.
DIABETOLOGIA (2003)
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
The metabolism of diclofenac - Enzymology and toxicology perspectives
W Tang
CURRENT DRUG METABOLISM (2003)
Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes
D Projean et al.
XENOBIOTICA (2003)
Cytochrome P4502C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes
KA Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2003)
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers
J Kirchheiner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6
T Prueksaritanont et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro
JS Wang et al.
DRUG METABOLISM AND DISPOSITION (2003)
Cytochrome P4502C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans
M Attar et al.
DRUG METABOLISM AND DISPOSITION (2003)
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes
JS Wang et al.
DRUG METABOLISM AND DISPOSITION (2002)
Gemfibrozil greatly increases plasma concentrations of cerivastatin
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes
N Bahadur et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
U Yasar et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
The effect of fluconazole on the pharmacokinetics of rosuvastatin
KJ Cooper et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A
A Soyama et al.
PHARMACOLOGY & TOXICOLOGY (2002)
Rhabdomyolysis associated with cerivastatin: Six cases within 3 months at one hospital
RA Lucas et al.
PHARMACOTHERAPY (2002)
Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8:: A new high affinity and turnover enzyme-specific probe substrate
XQ Li et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism
A Soyama et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2001)
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
D Dai et al.
PHARMACOGENETICS (2001)
Rhabdomyolysis and HMG-CoA reductase inhibitors
MA Omar et al.
ANNALS OF PHARMACOTHERAPY (2001)
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
G Somlo et al.
BRITISH JOURNAL OF CANCER (2001)
Clinical pharmacokinetics of fluvastatin
CD Scripture et al.
CLINICAL PHARMACOKINETICS (2001)
Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis
GP Aithal et al.
PHARMACOGENETICS (2000)
Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes
JO Miners et al.
PHARMACOGENETICS (2000)
Share Paper
